Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/1999
10/28/1999WO1999054546A1 Resin-impregnated belt having a texturized outer surface for application on papermaking machines
10/28/1999WO1999054464A1 MUTATED PEPTIDE COMPOUNDS, DERIVED FROM hsp70, USEFUL IN CANCER IMMUNOTHERAPY
10/28/1999WO1999054459A2 Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
10/28/1999WO1999054456A1 ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF INTEGRIN αv-SUBUNIT EXPRESSION
10/28/1999WO1999054440A1 CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
10/28/1999WO1999054408A1 Trans-xanthophyll ester concentrates of enhanced purity and methods of making same
10/28/1999WO1999054349A2 Dermatophagoides nucleic acid molecules, proteins and uses thereof
10/28/1999WO1999054341A1 Enhanced antisense modulation of icam-1
10/28/1999WO1999054336A1 (alpha-aminophosphino) peptidesderivative and compositions containing same
10/28/1999WO1999054333A1 Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
10/28/1999WO1999054331A1 Novel asymmetrically substituted xanthine derivatives, method for producing them and their use as medicaments with an adenosine-antagonistic effect
10/28/1999WO1999054330A1 2,3-olefinic epothilone derivatives
10/28/1999WO1999054329A1 Novel 2-heterocyclically substituted dihydropyrimidines
10/28/1999WO1999054326A1 Dihydropyrimidines
10/28/1999WO1999054323A1 Production of furanones
10/28/1999WO1999054320A1 Novel heterocyclically substituted amides with cysteine protease-inhibiting effect
10/28/1999WO1999054319A1 12,13-modified epothilone derivatives
10/28/1999WO1999054318A1 12,13-cyclopropane epothilone derivatives
10/28/1999WO1999054315A2 Triazolones with a neuroprotective action
10/28/1999WO1999054314A1 Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments
10/28/1999WO1999054313A1 Bicyclic compounds having an anti-thrombitic effect
10/28/1999WO1999054312A1 The use of dihydropyrimidines as medicaments, and novel substances
10/28/1999WO1999054311A1 Novel diphenyl-substituted 6-ring-heterocycles, methods for producing them and their use as medicaments
10/28/1999WO1999054310A2 New substituted amides, their production and their use
10/28/1999WO1999054308A1 5-aminoindeno(1,2-c)pyrazol-4-ones as anti-cancer and anti-proliferative agents
10/28/1999WO1999054306A1 Isoquinolinesulfonamide derivatives and drugs containing the same as the active ingredient
10/28/1999WO1999054305A1 Heterocyclically substituted amides used as calpain inhibitors
10/28/1999WO1999054304A1 Heterocyclically substituted amides, their production and their use
10/28/1999WO1999054302A1 Process for the production of r-(+)-6- carboxamido- 3-n- methylamino- 1,2,3,4- tetrahydrocarbazole
10/28/1999WO1999054301A1 Substituted 2-oxo-alkanoic acid-[2-(indol-3-yl)-ethyl] amides
10/28/1999WO1999054299A1 Pyrrolidines as inhibitors of neuraminidases
10/28/1999WO1999054298A1 Method for producing enantiomer-free n-methyl-n- [(1s)-1-phenyl- 2-((3s)- 3-hydroxypyrrolidine- 1-yl)ethyl]- 2,2-diphenyl acetamide
10/28/1999WO1999054294A1 New substituted amides, their production and their use
10/28/1999WO1999054293A1 Substituted benzamides, their production and their use as cysteine protease inhibitors
10/28/1999WO1999054290A1 Inhibitors of neuraminidases
10/28/1999WO1999054286A2 Btk inhibitors and methods for their identification and use
10/28/1999WO1999054284A1 Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
10/28/1999WO1999054280A1 Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation
10/28/1999WO1999054278A1 1-(2-ALKOXY-5-CARBOXYPHENYL)-α,β-UNSATURATED KETONES, THEIR PREPARATION AND APPLICATION IN THERAPEUTICS
10/28/1999WO1999053968A1 Solid borate-diol interaction products for use in wounds
10/28/1999WO1999053962A1 Solution for diagnosing or treating tissue pathologies
10/28/1999WO1999053958A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
10/28/1999WO1999053957A1 Estradiol-containing percutaneous absorption preparations
10/28/1999WO1999053956A1 Remedies for obesity
10/28/1999WO1999053953A2 Methods and products related to metabolic interactions in disease
10/28/1999WO1999053937A1 Immunopotentiators and antitumor agents
10/28/1999WO1999053935A1 Novel synergistic compositions containing aromatic compounds and terpenoids present in alpinia galanga
10/28/1999WO1999053930A1 Synthetic glycoamines and methods for their use, alone or in combination with other therapies, that affect cell adhesion, inhibit cancer cell growth and metastasis, and induce apoptosis
10/28/1999WO1999053928A1 Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
10/28/1999WO1999053927A1 Methods for treating and preventing insulin resistance and related disorders
10/28/1999WO1999053926A1 Use of a glucocorticosteroid for the manufacture of a medicament for treating mild/early forms of copd (chronic obstructive pulmonary disease)
10/28/1999WO1999053923A1 Pharmaceutical composition
10/28/1999WO1999053922A1 Analgesic compositions comprising nmda-antagonists and abt-594
10/28/1999WO1999053921A1 Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph
10/28/1999WO1999053920A1 Use of vitamin pp compounds
10/28/1999WO1999053919A1 Treatment of generalized anxiety disorder with paroxetine
10/28/1999WO1999053918A1 Stabilized compositions containing benzimidazole-type compounds
10/28/1999WO1999053917A1 Cannabinoids as antioxidants and neuroprotectants
10/28/1999WO1999053916A1 Anti-chlamydia agents
10/28/1999WO1999053915A1 Inhibition of gram positive bacteria
10/28/1999WO1999053914A1 Remedies for primary biliary cirrhosis
10/28/1999WO1999053913A1 Topical formulations for the treatment of nail fungal diseases
10/28/1999WO1999053912A1 Topical immunostimulation to induce langerhans cell migration
10/28/1999WO1999053911A1 Antifungal agents
10/28/1999WO1999053910A2 Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
10/28/1999WO1999053909A2 Pharmaceutical composition for neurotrophic action
10/28/1999WO1999053908A2 Pro-drug conjugates for the treatment of stroke and other ischaemic conditions
10/28/1999WO1999053907A2 Composition for treating psoriasis containing evening primrose oil and vitamins e and b
10/28/1999WO1999053906A1 Adhesive preparations
10/28/1999WO1999053904A2 Softgel-compatible composition containing retinol
10/28/1999WO1999053901A1 Pharmaceutical aerosol formulation
10/28/1999WO1999053899A1 Medicinal compositions for application to mucosa
10/28/1999WO1999053898A1 Implants for administering substances and methods of producing implants
10/28/1999WO1999053897A2 Topical formulation comprising poloxamers and further microbicides, and an applicator
10/28/1999WO1999053895A1 Use of unsymmetrically substituted triazine derivatives in cosmetic or dermatological preparations for maintaining the urocanic acid status of the skin
10/28/1999WO1999053756A1 Pre-operative beverage composition and method of treatment
10/28/1999WO1999044588A3 Method for producing solid, spherical forms containing pharmaceutical active agents in a binder matrix
10/28/1999WO1999043654A3 Inhibitors of phospholipase enzymes
10/28/1999WO1999043308A3 Treating pulmonary hypertension through tenascin suppression and elastase inhibition
10/28/1999WO1999042839A3 Treating cancer
10/28/1999WO1999042093A3 Antagonists of a2b human adenosine receptors
10/28/1999WO1999042089A9 Use of thiadiazolo[4,3-a]pyridine derivatives
10/28/1999WO1999041404A3 Novel means and methods for the preparation and activation of nucleoside and nucleotide based drugs
10/28/1999WO1999041237A8 Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
10/28/1999WO1999040946A3 Methods and compositions for modulating leptin activity
10/28/1999WO1999039740A3 Sensitizing cells to compounds using lipid-mediated gene and compound delivery
10/28/1999WO1999039691A3 Pharmaceutical compositions
10/28/1999WO1999037150B1 Transcription therapy for cancers
10/28/1999WO1999036063A9 Vanadium (iv) metallocene complexes having spermicidal activity
10/28/1999WO1999035243A9 Extension of cellular lifespan, methods and reagents
10/28/1999WO1999034832A8 Crystallographically stable amorphous cephalosporin compositions and process for producing the same
10/28/1999WO1999033858A9 Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
10/28/1999WO1999033846A3 Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
10/28/1999WO1999024460B1 Dipeptide nitriles
10/28/1999WO1999021540B1 Method of reducing craving in mammals
10/28/1999WO1999004773A9 Method for inhibiting bone resorption
10/28/1999WO1997029739A3 Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors
10/28/1999DE19818914A1 Verwendung von peroxidierten organischen Verbindungen mit "aktiviertem Sauerstoff" zur Verbesserung der Mikrozirkulation des Blutes in der Haut Use of peroxidized organic compounds with "activated oxygen" to improve the microcirculation of blood in the skin
10/28/1999DE19818802A1 Stable mitoxantron solutions useful for cancer therapy
10/28/1999DE19818696A1 Protection of organ, especially lung, transplants against rejection
1 ... 6421 6422 6423 6424 6425 6426 6427 6428 6429 6430 6431 6432 6433 6434 6435 6436 6437 6438 6439 6440 6441 ... 7860